Recombinant Human UBE2I Protein (N-GST)

Name: Recombinant Human UBE2I Protein (N-GST)
Brand: Beta LifeScience
SKU: BL-0269NP
Availability: InStock

BL-0269NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Ubiquitin-Conjugating Enzyme E2 I is produced by our E.coli expression system and the target gene encoding Met1-Ser158 is expressed with a GST tag at the N-terminus.
Accession	P63279
Synonym	SUMO-Conjugating Enzyme UBC9; SUMO-Protein Ligase; Ubiquitin Carrier Protein 9; Ubiquitin Carrier Protein I; Ubiquitin-Conjugating Enzyme E2 I; Ubiquitin-Protein Ligase I; p18; UBE2I; UBC9; UBCE9
Gene Background	SUMO-Conjugating Enzyme UBC9 (UBC9) belongs to the ubiquitin-conjugating enzyme family. UBC9 is homologous to ubiquitin-conjugating enzymes (E2s). However, instead of conjugating ubiquitin, UBC9 conjugates a ubiquitin homologue, Small Ubiquitin-Like Modifier 1 (SUMO-1). The conjugation of ubiquitin requires the activities of ubiquitin-activating (E1) and conjugating (E2) enzymes. It is suggested that UBC9 might play a role in DNA repair and perhaps even in aging.
Molecular Mass	44.4 KDa
Apmol Mass	40 KDa, reducing conditions
Formulation	Supplied as a 0.2 μm filtered solution of 50mM HEPES, 150mM NaCl, pH 7.5.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution
Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Mediates sumoylation of ERCC6 which is essential for its transcription-coupled nucleotide excision repair activity.
Subcellular Location	Nucleus. Cytoplasm.
Protein Families	Ubiquitin-conjugating enzyme family
Database References	HGNC: 12485 OMIM: 601661 KEGG: hsa:7329 STRING: 9606.ENSP00000324897 UniGene: PMID: 29956745 Data show that the forkhead Box Protein P3 (FOXP3) response element at the -310 bp region, but not the -2182 bp region, is mainly required for ubiquitin conjugating enzyme 9 (UBC9) activation by FOXP3. PMID: 30011797 Study provides an insight into the role of the RNF4 to balance the role of SUMO signaling by directly targeting Ubc9 and SUMO E3 ligases. PMID: 29180619 The SUMO1/UBC9 axis may regulate Nox1mediated diabetic retinopathy by inhibiting reactive oxygen species generation and apoptosis. PMID: 29138839 our results indicate that down-regulation of UBC9 sensitizes cells to anticancer drugs, is possibly associated with the regulation of ERK1/2 and P38 activation and interacts with the intrinsic apoptosis pathway. PMID: 28572537 Ubc9 is an essential regulator of ADAP where it is required for TCR-induced membrane recruitment of the small GTPase Rap1 and its effector protein RapL and for activation of the small GTPase Rac1 in T cell adhesion. PMID: 29127148 NUSAP1 contributes to accurate chromosome segregation by acting as a co-factor for RanBP2-RanGAP1-UBC9 during cell division. PMID: 28900032 Listeriolysin O -induced down-regulation of Ubc9 is independent of Ubc9-SUMO interaction, however, it may involve phosphorylation signaling. PMID: 28911869 Sumoylation of PML with SUMO2 by UBC9/UBE2I can lead to formation of polymeric SUMO chains. Data suggest that coordination of growing poly-SUMO chain with "back side" binding site on UBC9/UBE2I appears to be required for SUMO chain elongation on PML. (PML = promyelocytic leukemia protein; SUMO2 = small ubiquitin-like modifier 2; UBC9/UBE2I = ubiquitin-conjugating enzyme UBC9/UBE2I) PMID: 28784659 The role of Transthyretin in the regulation of Ubc9 SUMOylation PMID: 27501389 These findings point to UBC9 and autophagy as novel hallmarks of human papillomavirus oncogenesis PMID: 28253371 These findings reveal that SUMO E1~E2 oxidation is an essential redox switch in oxidative stress. PMID: 27174643 the mRNA and protein expression of Ubc9 are regulated by the microRNA miRNA-30a (miR-30a) in human subcutaneous adipocytes. PMID: 27758866 miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs. More specifically, it was demonstrated that miR-30e exhibited these effects on VSMCs partially through targeting Ube2i and downregulating the IkappaBalpha/NFkappaB signaling pathway. PMID: 28123167 Ubc9 plays different roles of action in antitumor agents in chemotherapy. The process requires bleomycin hydrolase and poly(ADP-ribose) polymerase-1. The results are beneficial to deeply understanding of Ubc9 functions and for precise prediction of chemotherapy outcomes in tumors. PMID: 27878232 Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. PMID: 27030546 Akt directly phosphorylates Ubc9 at Thr35 and phosphorylates SUMO1 at Thr76. Ubc9 phosphorylation at Thr35 promotes Ubc9 thioester bond formation and SUMO1 phosphorylation at Thr76 stabilizes the SUMO1 protein. PMID: 25867063 Characterization and Structural Insights into Selective E1-E2 Interactions in the Human and Plasmodium falciparum SUMO Conjugation Systems. PMID: 26697886 a high-throughput microscopy screen identified ubiquitin carrier protein 9 (Ubc9) as a negative regulator of energy storage in human sc adipocytes. Ubc9 depletion enhanced energy storage and induced the brown fat gene program in human sc adipocytes. PMID: 26192107 The authors show that ZNF451 is SUMO2 specific and that SUMO modification of ZNF451 may contribute to activity by providing a second molecule of SUMO that interacts with E2. PMID: 26524494 The RWD domain binds to a Ubc9 surface that also must interact with E1, E3, and SUMO. PMID: 25918163 These data show that NS5A is a target protein of small ubiquitin-like modifier (SUMO) and is SUMOylated at lysine residue 348 and silencing of UBC9 impaired hepatitis C virus replication. PMID: 24602294 SUMO E2 ligase Ubc9 has a critical role in oncogenesis driven by the Ras/Raf pathway PMID: 25805818 Ubc9 gene plays an important role in cell proliferation in epithelial ovarian cancer through PI3K/Akt signaling pathway. PMID: 23708104 Data indicate that protein tyrosine phosphatase 1B (PTP1B) association with calnexin is ubiquitin conjugating enzyme 9 (UBC9)-dependent. PMID: 25586181 N-terminal amino acid residues of Ubc9 are critical for Ubc9 nuclear enrichment and localization. PMID: 25637535 the Ran system and Ubc9 are functionally coupled to the structure of the nuclear lamina and reactive oxygen species production through feedback loops PMID: 24523287 Although E2 approximately SUMO-1 exhibits no specificity for product-bound TDG, the relatively high conjugation efficiency raises the possibility that E2-mediated sumoylation could stimulate product release in vivo. PMID: 24753249 The variability of the UBC9 gene can play a role in breast cancer occurrence. PMID: 23873416 UBC9 appears to play an important role in the tumor biology of Nigerian women. PMID: 24176171 miR-214 and its target gene UBC9 may contribute to the development and the clinical outcome of glioma PMID: 24277415 The proximal UBC9 promoter. PMID: 24086615 Study showed that ZHX1 is SUMOylated by Ubc9 with SUMO1 at the sites K159, K454, and K626 and that the SUMOylation of ZHX1 regulated the stability, ubiquitination and transcriptional activity of ZHX1. PMID: 23686912 This study provides further insight in the processing and packaging of the HIV-1 gp120 into mature HIV-1 virions. PMID: 23861967 We observed steady-state expression of SUMO-conjugated enzyme-UBC9 throughout normal gestation. Placental UBC9 levels were strikingly increased in severe pre-eclampsia patients. PMID: 23628505 These results suggest that the SUMOylation of DDB2 facilitates CPD repair. PMID: 23860269 we demonstrated that upregulation of Ubc9 expression promotes migration and invasion. Ubc9 likely plays an important role in cancer progression by promoting invasion and metastasis in lung cancer. PMID: 23381475 High UBC9 expression is associated with glioma. PMID: 23187003 From these observations, we concluded that UBC9 is a novel regulator of the mammalian ER stress response. PMID: 23470653 The E2 enzyme Ubc9 is an interaction partner of E1B-55K, providing a possible molecular explanation for SUMO-dependent modulation of cellular target proteins. PMID: 22614022 A previously undescribed SIRT1/Ubc9 regulatory axis in the modulation of protein sumoylation and the hypoxia response. PMID: 23395904 High Ubc9 expression correlates with poor response to chemotherapy and poor clinical prognosis in breast cancer. PMID: 21880185 Data show that the SAE2 subunit of the small ubiquitin-like modifier (SUMO) E1 is autoSUMOylated at residue Lys-236, and SUMOylation was catalyzed by Ubc9 at several additional Lys residues surrounding the catalytic Cys-173 of SAE2. PMID: 22403398 UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PMID: 22114711 There was no statistical association of UBE2I expression between human epithelial ovarian cancer tumor and normal tissues PMID: 21971700 Ubc9 and PIAS1 potentiated SF-1-mediated transactivation of human CYP17, CYP11A1, and CYP11B1 but not CYP11B2 promoters. PMID: 21467194 Binding of BRCA1 proteins to nuclear chaperone Ubc9 provides a novel mechanism for nuclear import and control of tumor growth. PMID: 21344391 The authors propose that LMP1, by interaction with Ubc9, modulates sumoylation processes, which regulate signal transduction pathways that affect phenotypic changes associated with oncogenesis. PMID: 21795333 The authors report that the high risk human papillomavirus E6 proteins reduce the intracellular quantity of the sole SUMO conjugation enzyme, Ubc9, concomitant with decreased host sumoylation. PMID: 21510985 Analysis of the dynamics of E2(Ubc9)-SUMO-Target(RanGAP1) in the absence and presence of E3(RanBP2) revealed that two different allosteric sites regulate the ligase activity. PMID: 21216249

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human UBE2I Protein (N-GST)

Recombinant Human UBE2I Protein (N-GST)

Product Overview

Target Details

FAQs